
BLTE Stock Forecast & Price Target
BLTE Analyst Ratings
Bulls say
Belite Bio is well-funded with $772.6M in cash and investments, which is sufficient to complete the FDA regulatory process, commercially launch tinlarebant, and continue ongoing clinical trials. This financial stability, along with a strong pipeline and favorable probabilities of approval for their product candidates, makes Belite Bio a promising investment opportunity with potential for significant growth. However, there are risks to consider, such as potential failure in clinical trials or securing regulatory approval, and competition in the market.
Bears say
Belite Bio is expected to complete a rolling submission of a New Drug Application (NDA) for tinlarebant, its novel oral therapy for Stargardt disease type 1 (STGD1), by the end of 2026, and potentially obtain FDA approval by the end of 2026. The company's planned sales team of 25-30 personnel will focus on genetic testing awareness to identify the estimated 53,000 U.S. patients with ABCA4-mutated STGD1, potentially allowing for a broad label for all patients above 12 years of age with similar genetic pathology. However, given the clinical stage of Belite Bio and the competitive landscape for degenerative retinal disease treatments, we believe there is considerable risk for delays in FDA approval and commercial success.
This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
BLTE Analyst Forecast & Price Prediction
Start investing in BLTE
Order type
Buy in
Order amount
Est. shares
0 shares